ArticleEuropean journal of clinical pharmacology2026
Effect of transporter gene polymorphisms and valproate co-medication on the steady-state disposition of lamotrigine and their effect on efficacy in adults with epilepsy.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background and Objectives The steady-state disposition lamotrigine (LTG) varies widely among patients with epilepsy, especially in the presence of concomitant antiseizure drugs. In this study, we investigate the potential role of transporter gene polymorphisms in ABCC1, ABCC2, ABCG2, SLCO1A2 and SLCO1B1 on the steady-state disposition of LTG and on the lamotrigine-valproate (LTG-VPA) interaction, and their effect on the therapeutic efficacy in adults with epilepsy.Methods Adults with epilepsy on LTG monotherapy or LTG-VPA treatment were genotyped and steady-state LTG and VPA morning troughs were determined. The number of seizures within a one-year follow-up period was used to evaluate the antiepileptic efficacy.Results A total of 331 patients with epilepsy were enrolled, including 267 receiving LTG monotherapy and 64 receiving LTG combined with VPA. Steady-state LTG plasma troughs and normalized troughs were significantly higher in the LTG-VPA group than in the LTG monotherapy group (8.82 vs. 4.43 µg/mL, p < 0.001; 4.12 vs. 1.51 µg/mL, p < 0.001). Among the investigated transporter gene polymorphisms, only SLCO1B1 rs4149032 showed a significant association with LTG concentrations in monotherapy. Overall, 77.8% (242/331) of patients achieved a therapeutic response, with a markedly higher response rate in the LTG-VPA group compared with LTG alone (92.1% vs. 76.5%, p = 0.0009). Multivariate logistic regression identified LTG plasma concentration and sex as independent predictors of favorable seizure control.Conclusions The polymorphisms of SLCO1B1 rs4149032 may affect LTG plasma troughs in patients with LTG monotherapy. LTG plasma concentrations are a major determinant of antiepileptic therapeutic efficacy with or without VPA co-therapy, with higher exposure associated with improved seizure control.
Indexed as
Identifiers
41786984What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.